These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

678 related articles for article (PubMed ID: 1373963)

  • 41. Prenatal diagnosis, fetal surgery, recurrence risk and differential diagnosis of neural tube defects.
    Chen CP
    Taiwan J Obstet Gynecol; 2008 Sep; 47(3):283-90. PubMed ID: 18935990
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Maternal serum alpha-fetoprotein screening: promise not yet fulfilled.
    Nadler HL; Simpson JL
    Am J Obstet Gynecol; 1979 Sep; 135(1):1-2. PubMed ID: 89812
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lens culinaris agglutinin-reactive alpha-fetoprotein, an alternative variant to alpha-fetoprotein in prenatal screening for Down's syndrome.
    Yamamoto R; Azuma M; Hoshi N; Kishida T; Satomura S; Fujimoto S
    Hum Reprod; 2001 Nov; 16(11):2438-44. PubMed ID: 11679535
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Taking account of vaginal bleeding in screening for Down's syndrome.
    Cuckle H; van Oudgaarden ED; Mason G; Holding S
    Br J Obstet Gynaecol; 1994 Nov; 101(11):948-53. PubMed ID: 7528053
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [A study on population-based prenatal screening and diagnosis of Down's syndrome in Jiangsu province].
    Liu QL; Hu YL; Xu ZF; Wang LJ; Sun Q; Lin N; Xu XY; Liu Y; Zhang JW; Tong JS; Wang XH; He J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Jun; 27(3):340-2. PubMed ID: 20533279
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Screening for Down's syndrome and neural tube defect in Croatia. A regional prospective study.
    Brajenović-Milić B; Tislarić D; Bacić J; Paravić J; Slivar AE; Kapovic M; Kosec V; Ristic S; Rajhvajn B
    Fetal Diagn Ther; 1998; 13(6):367-71. PubMed ID: 9933821
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Free beta human choriogonadotropin in Down's syndrome screening: a multicentre study of its role compared with other biochemical markers.
    Spencer K; Coombes EJ; Mallard AS; Ward AM
    Ann Clin Biochem; 1992 Sep; 29 ( Pt 5)():506-18. PubMed ID: 1280026
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The importance of accurate gestational age estimation in screening for fetal neural tube defects using maternal serum alpha-fetoprotein levels.
    Kirkpatrick A; Cohen M; Prescott GH; Jones OW; Matson M; Wepsic HT
    UCLA Forum Med Sci; 1978; 20():199-205. PubMed ID: 80862
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Prenatal diagnosis of genetic defects from the amniotic fluid. Report of experiences].
    Körner H; Halle H; Wagenknecht C
    Zentralbl Gynakol; 1977; 99(12):725-34. PubMed ID: 70907
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in pregnancies with insulin-dependent diabetes: implications for screening for Down's syndrome.
    Wald NJ; Cuckle HS; Densem JW; Stone RB
    Br J Obstet Gynaecol; 1992 Jan; 99(1):51-3. PubMed ID: 1372176
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Prenatal diagnosis of neural tube and abdominal wall defects in the 2d trimester].
    Mühlhaus K; Weitzel HK; Schneider J
    Geburtshilfe Frauenheilkd; 1985 Feb; 45(2):98-100. PubMed ID: 2579872
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Second trimester screening for Down's syndrome: 7 years experience.
    Beaman JM; Goldie DJ
    J Med Screen; 2001; 8(3):128-31. PubMed ID: 11678551
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Strategies for antenatal detection of Down's syndrome.
    Wyllie JP; Madar RJ; Wright M; Burn J; Wren C
    Arch Dis Child Fetal Neonatal Ed; 1997 Jan; 76(1):F26-30. PubMed ID: 9059182
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Maternal serum unconjugated oestriol as an antenatal screening test for Down's syndrome.
    Wald NJ; Cuckle HS; Densem JW; Nanchahal K; Canick JA; Haddow JE; Knight GJ; Palomaki GE
    Br J Obstet Gynaecol; 1988 Apr; 95(4):334-41. PubMed ID: 2454652
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Empirical validation of risk screening for Down's syndrome.
    Wald NJ; Hackshaw AK; Huttly W; Kennard A
    J Med Screen; 1996; 3(4):185-7. PubMed ID: 9041482
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antenatal screening for Down's syndrome with the quadruple test.
    Wald NJ; Huttly WJ; Hackshaw AK
    Lancet; 2003 Mar; 361(9360):835-6. PubMed ID: 12642052
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assay precision of serum alpha fetoprotein in antenatal screening for neural tube defects and Down's syndrome.
    Wald NJ; Hackshaw AK; George LM
    J Med Screen; 2000; 7(2):74-7. PubMed ID: 11002446
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Prenatal recognition of genetic diseases and neural tube defects].
    Fuhrmann W
    Geburtshilfe Frauenheilkd; 1983 Jun; 43(6):399-404. PubMed ID: 6193031
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biochemical screening.
    Cuckle HS; Wald NJ
    Curr Opin Obstet Gynecol; 1990 Apr; 2(2):246-52. PubMed ID: 1714781
    [No Abstract]   [Full Text] [Related]  

  • 60. Antenatal screening for Down's syndrome: where are we and where next?
    Haddow JE
    Lancet; 1998 Aug; 352(9125):336-7. PubMed ID: 9717914
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.